SFM
CLDX icon

Sphera Funds Management’s Celldex Therapeutics CLDX Stock Holding History

Sphera Funds Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-115,700
Closed -$4.59M – 108
2023
Q4 		$4.59M Buy
115,700
+15,700
+16% +$462K 0.74% 50
2023
Q3 		$2.75M Buy
+100,000
New +$3.13M 0.5% 60

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sphera Funds Management's CLDX Position: Q2 2026 in Review

Sphera Funds Management reduced its Celldex Therapeutics (CLDX) stake by 1.1% in Q2 2026, selling an estimated $87.4K and leaving 240,868 shares worth $8.96M. The position accounts for 1.17% of the portfolio, ranked #23.

Sphera Funds Management first reported a position in CLDX in Q1 2015 and has held it in 19 quarters since. The position peaked at $14.2M in Q3 2024. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Sphera Funds Management held 240,868 shares of Celldex Therapeutics worth $8.96M as of Q2 2026.
  • Sphera Funds Management sold 2,707 Celldex Therapeutics shares in Q2 2026, an estimated $87.4K.
  • Celldex Therapeutics made up 1.17% of Sphera Funds Management's portfolio in Q2 2026, its #23 holding.
  • Sphera Funds Management first reported a position in Celldex Therapeutics in Q1 2015 and has held it in 19 quarters since.
  • Sphera Funds Management's Celldex Therapeutics position peaked at $14.2M in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.